NCT07187973View on ClinicalTrials.gov

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

October 31, 2027

Conditions

Sickle Cell Disease

Interventions

DRUG

DISC-3405

DISC-3405 is administered subcutaneously.

Sponsors

Lead Sponsor

Disc Medicine, Inc

All Listed Sponsors

lead

Disc Medicine, Inc

INDUSTRY

NCT07187973 - A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | Biotech Hunter | Biotech Hunter